---

Market Overview

---

Based on the latest research analysis, the global hematological malignancies emerging therapeutics industry is projected to experience a significant compound annual growth rate (CAGR) of 14.20% from 2021 to 2031. In 2021, the market was valued at $11,653 million, and it is expected to reach $43,967 million by 2031.

The growing interest of pharmaceutical companies in developing therapies for hematological malignancies has been a driving force behind the advancements in this market. While monoclonal antibodies have been the mainstay of commercialized products for treating hematological malignancies, there is an anticipated rise in the use of chimeric antigen receptor (CAR) T-cell therapy. CAR-T cell therapy offers potential advantages in addressing unmet medical needs, overcoming limitations of monoclonal antibodies, and targeting complex disease markers.

The growth of the hematological malignancies emerging therapeutics market can be attributed to several key factors. First, there is a rising prevalence of hematological malignancies worldwide. Additionally, a favorable regulatory environment has facilitated the development and approval of innovative therapies. Moreover, the adoption of precision medicine in the field of hematological malignancies has gained momentum, driving the demand for targeted therapies.

However, there are significant challenges that impede market growth. The high cost of these therapies hinders their adoption rate, particularly in resource-limited healthcare systems. The reimbursement scenario is also unfavorable in some regions, posing barriers to patient access. Furthermore, concerns about the safety of severe adverse effects associated with these therapies need to be addressed for wider acceptance.

The hematological malignancies emerging therapeutics market report provides a comprehensive overview, encompassing various factors influencing the market. These include clinical findings, financing and partnership opportunities, market outlook, and the current landscape of clinical trials.

The study focuses on monoclonal antibody (mAB) and chimeric antigen receptor (CAR) T-cell-based therapies for hematological malignancies. It offers an in-depth analysis of market dynamics and provides an estimation of the market size throughout the forecast period from 2021 to 2031.

---

Market Segmentation

---

The market is segmented based on various factors, including marketed drugs, potential pipeline products, indication, and region.

Segmentation by Marketed Drugs
Monoclonal Antibodies
CAR-T Cell Therapy

Segmentation by Potential Pipeline Products
Monoclonal Antibodies
CAR-T Cell Therapy

Segmentation by Indication
Leukemia
Lymphoma
Multiple Myeloma

Segmentation by Region
North America – U.S. and Canada
Europe – Germany, U.K., France, Italy, and Spain
Asia-Pacific – China, Japan, and South Korea
Rest-of-the-World

The projected revenue for the marketed drugs segment is expected to reach $43,967 million in 2031, exhibiting a CAGR of 14.20% during the forecast period of 2021-2031. This significant growth is attributed to the commercialization of monoclonal antibodies and CAR-T cell therapy products designed to treat various forms of hematological malignancies. In 2020, the monoclonal antibodies segment accounted for the largest share of the market, representing 86.36% of total marketed products. However, CAR-T cell therapy is anticipated to experience rapid growth, with a projected CAGR of 19.17% during the forecast period, reaching $9,720 million in 2031.

The success of monoclonal antibodies can be attributed to years of continuous innovations in the field, which have demonstrated their potential in treating different indications of hematological malignancies. The revenue generated from marketed monoclonal antibodies drugs includes products such as Blincyto, Besponsa, Lumoxiti, Mylotarg, Opdivo, AiRuiKa, Tyvyt, Tislelizumab, Gazyva, Zynlonta, Darzalex, Blenrep, Keytruda, and Adcetris, all of which are utilized in the treatment of various hematological malignancies.

Darzalex, a CD38-directed cytolytic antibody, is projected to reach $15,214 million in revenue by 2031, growing at a CAGR of 9.71% from its 2020 value of $4,190 million. The increased prevalence of multiple myeloma worldwide is driving this growth. In 2019, the global prevalence of multiple myeloma was reported to be 457,473 cases, showing a 6.35% increase compared to the 430,165 cases in 2017. Darzalex works by targeting CD38 proteins found on the surface of plasma cells, inhibiting their growth and initiating apoptosis (cell death). This drug was developed jointly by Genmab A/S and Johnson & Johnson Services, Inc., with the latter acquiring exclusive commercialization rights globally. Darzalex gained various approvals, including its initial approval by the U.S. Food and Drug Administration on November 16, 2015, for the treatment of multiple myeloma patients who have received at least three prior treatments.

The potential pipeline products segment is expected to reach $3,083 million in revenue by 2031, growing from its 2022 value of $47.5 million. This revenue includes contributions from monoclonal antibodies and CAR-T cell therapy products that are currently being evaluated for their efficacy as monotherapy treatments for various hematological malignancies. Only pipeline products in their late development phase that have met their primary endpoints are considered. By 2031, it is projected that the monoclonal antibodies segment will hold 71.97% of total potential pipeline products, while the CAR-T cell therapy segment will hold 28.03%. CAR-T cell therapy is an emerging and promising approach in cancer treatment, particularly in hematologic malignancies, with a history of improving patient outcomes.

Researchers are actively investigating several drugs for hematological malignancies, including leukemia, multiple myeloma, and lymphoma, with the aim of developing potent monoclonal- and gene-based therapies. Multiple myeloma had the largest market share in 2020, accounting for 50.15% of cases, followed by lymphoma at 42.03%, and leukemia at 7.83%. The multiple myeloma lymphoma segment is projected to reach $19,539 million in revenue by 2031, growing at a CAGR of 12.09% during the forecast period. Multiple myeloma is characterized by abnormal plasma cell development and is more common in men than women, often occurring around the age of 60. As the disease progresses, symptoms such as kidney dysfunction, bone pain, anemia, and infections may manifest.

In 2020, the global market for hematological malignancies emerging therapeutics was valued at $8,445 million and is expected to reach $43,967 million by 2031. The North America region accounted for the largest share of the market in 2020, with a value of $4,130 million. This can be attributed to increased research and development activities in the region, as well as the growing prevalence of hematological malignancies such as leukemia and lymphoma. Moreover, North America is home to several biopharmaceutical manufacturers engaged in developing emerging therapeutics to enhance the quality of life for cancer patients. These factors contribute to the market’s dominance in North America. However, the Asia-Pacific region, comprising several emerging economies, is anticipated to exhibit the highest CAGR of 14.68% during the forecast period of 2021-2031.

---

Competitive Landscape

---

Key companies profiled in this report include AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Immune-Onc Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited

---

Key Questions Answered

---

What are the primary market drivers, challenges, and opportunities in the global market for emerging therapeutics for hematological malignancies?

What are the underlying factors contributing to the emerging trends within the global market for emerging therapeutics in hematological malignancies?

How has the COVID-19 pandemic impacted the ecosystem of emerging therapeutics for hematological malignancies on a global scale?

What are the key development strategies being implemented by major players to sustain their competitiveness in the market?

What is the current pricing and reimbursement landscape in the field of emerging therapeutics for hematological malignancies?

What potential emerging therapies are currently in the pipeline for the treatment of hematological malignancies?

What are the significant regulatory implications in developed and developing regions concerning emerging therapeutics for hematological malignancies?

What potential barriers to entry are expected to be encountered by companies wishing to enter specific regions?

How is each market segment expected to grow during the forecast period of 2021-2031, and what revenue is anticipated to be generated by each segment?

What role do companion diagnostics play in the field of emerging therapies for hematological malignancies, and what are the key regulatory requirements associated with them?

What growth opportunities exist for companies operating in their respective regions?

Who are the leading players with significant offerings in the global market for emerging therapeutics in hematological malignancies?

Which companies are expected to have a highly disruptive impact in the future, and what are the reasons behind this anticipation?